2-benzyl-3,3-dimethylbutanal

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzyl-3,3-dimethylbutanal
• 英文别名: 2-Benzyl-3,3-dimethylbutanal
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: SWAZYIZSZJQBRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-benzyl-2-(tert-butyl)oxirane 在 硫酸 作用下， 反应 0.25h， 以9%的产率得到2-benzyl-3,3-dimethylbutanal
  参考文献：
  名称：

  通过新戊环氧化物的酸催化环异构化合成邻位四元全碳中心。

  摘要：

  我们报告了我们对 2,2-二取代的新戊基环氧化物的催化环异构化反应的研究，以生产高度取代的四氢萘和色满。序列的终止通过远程（杂）芳烃接头的 Friedel-Crafts 型烷基化发生。硫酸可有效促进转化，并在 1,1,1,3,3,3-六氟异丙醇 (HFIP) 作为溶剂中进行得最好。取代模式的变化提供了对迁移趋势的详细见解，并揭示了二氢萘的竞争歧化途径。

  DOI：

  10.1021/acs.orglett.0c02296

文献信息

• Cytotoxic peptides and conjugates thereof
  申请人：NOVARTIS AG

  公开号：US10280139B2

  公开（公告）日：2019-05-07

  Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

  本文公开了如本文所述的新型式 (I) 化合物： 本发明还描述了免疫结合剂（即抗体药物结合剂），其包含与抗原结合分子（如抗体）连接的此类新型化合物；其中此类免疫结合剂可用于治疗细胞增殖性疾病。本发明进一步提供了包含这些免疫共轭物的药物组合物、包含这些免疫共轭物与治疗共用试剂的组合物，以及使用这些免疫共轭物和组合物治疗细胞增殖障碍的方法。
• Brémand, Nathalie; Normant, Jean F.; Mangeney, Pierre, Synlett, 2000, # 4, p. 532 - 534
  作者：Brémand, Nathalie、Normant, Jean F.、Mangeney, Pierre

  DOI：——

  日期：——
• COMPOSITIONS CONTAINING A CELLULOSE DERIVED CAPSULE WITH A SUNSCREEN ACTIVE AGENT
  申请人：Colabs International Corporation

  公开号：EP3413981A1

  公开（公告）日：2018-12-19
• TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF
  申请人：Mersana Therapeutics, Inc.

  公开号：US20170119896A1

  公开（公告）日：2017-05-04

  A terminally modified polymer is provided herein. At least one terminus of the polymer is —O—(CH 2 ) 2 -L M or —O—CH 2 —CH(OH)—CH 2 —CR 1 ═CR 2 R 3 . L M , R 1 , R 2 , and R 3 are defined herein Also disclosed are terminal conjugates comprising the polymer and a pharmaceutically useful modifier, as well as compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.
• AURISTATIN DERIVATIVES AND CONJUGATES THEREOF
  申请人：Geierstanger Bernhard Hubert

  公开号：US20170121282A1

  公开（公告）日：2017-05-04

  Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.